Inhibition of the RANKL with denosumab has no effect on circulating markers of atherosclerosis in women with postmenopausal osteoporosis: a pilot study

Autor: Sara Piemonte, Valentina Piazzolla, Viviana De Martino, Salvatore Minisola, Federica Ferrone, Luciano Nieddu, Luciano Colangelo, Jessica Pepe, Daniele Diacinti, Valeria Fassino, Cristiana Cipriani
Rok vydání: 2020
Předmět:
Zdroj: Endocrine. 71:199-207
ISSN: 1559-0100
1355-008X
Popis: We evaluated the early effect of denosumab on circulating markers of atherosclerosis in women with postmenopausal osteoporosis. Denosumab (60 mg) was administered subcutaneously every 6 months (m) in 27 women (mean age 75 ± 5 years) with postmenopausal osteoporosis and high cardiovascular risk for a total of 24 m. Zoledronic acid was administered in 6 age-matched women as a single intravenous dose. Serum levels of vascular cell adhesion protein 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), E and P selectin, CD-40 ligand (CD40L), interleukin-6 (IL-6), matrix metalloproteinase (MMP) 1 and 9, monocyte chemoattractant protein-1 (MCP-1), fibrinogen (FBG), and high sensitivity C-reactive protein (hs-CRP) were measured at baseline, 15 days (d), 2, 6 and 12 m after dosing. In the denosumab group, observation was extended to 24 m as secondary endpoint. Serum ICAM-1 levels showed significant increase in the zoledronic acid group (+18 ± 0.1%; p
Databáze: OpenAIRE